Sio Capital Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Sio Capital Management, LLC reported 45 stock positions worth $287.0 million. Its top holding was Laboratory CRP of Amer (LH) at 17.2% of the portfolio, followed by Cigna (CI, 9.6%) and Globus Medical Class A (GMED, 7.4%). Compared with Q4 2023, it opened 21 new positions, sold out of 12, added to 4 and reduced 11. The biggest buy was Laboratory CRP of Amer (LH, shares +37%) and the biggest sale an exit from Mirati Therapeutics (MRTX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001482416
- Portfolio Value
- $287.0M (Q1 2024)
- SEC Filing
- 0001214659-24-009242 ↗ filed May 15, 2024
Holdings Value
Holdings 45 stocks · $287.0M
| LH Laboratory CRP of Amer Hldgs | 17.20% | 225,902 | $49.4M | Add +36.8% |
| CI The Cigna Group | 9.63% | 76,086 | $27.6M | Reduce -34.7% |
| GMED Globus Medical Inc. Class A | 7.35% | 393,420 | $21.1M | Reduce -26.1% |
| MDGL Madrigal Pharmaceuticals Inc. | 4.75% | 51,000 | $13.6M | New |
| GSK GSK PLC-Spon ADR | 3.94% | 263,445 | $11.3M | Reduce -53.9% |
| ZBH Zimmer Biomet Holdings Inc. | 3.41% | 74,179 | $9.8M | Add +2.6% |
| MDT Medtronic PLC | 3.19% | 105,000 | $9.2M | New |
| OGN Organon & Co. | 3.14% | 479,023 | $9.0M | New |
| TYRA Tyra Biosciences Inc. | 3.06% | 535,741 | $8.8M | New |
| EMBC Embecta Corp. | 2.71% | 585,418 | $7.8M | Reduce -20.5% |
| TFX Teleflex Inc. | 2.67% | 33,878 | $7.7M | Reduce -7.3% |
| ARQT Arcutis Biotherapeutics Inc. | 2.20% | 635,969 | $6.3M | No change |
| BBIO Bridgebio Pharma Inc. | 2.19% | 203,174 | $6.3M | Add +54.2% |
| HUMA Humacyte Inc. | 2.17% | 2,000,000 | $6.2M | New |
| ANIP Ani Pharmaceuticals Inc. | 2.10% | 87,354 | $6.0M | New |
| ATXS Astria Therapeutics Inc. | 2.01% | 410,267 | $5.8M | New |
| SPRY Ars Pharmaceuticals Inc. | 1.91% | 536,163 | $5.5M | Reduce -51.5% |
| HCSG Healthcare Services Group | 1.83% | 421,317 | $5.3M | Reduce -48.0% |
| APGE Apogee Therapeutics Inc. | 1.81% | 78,000 | $5.2M | New |
| FUSN Fusion Pharmaceuticals Inc. | 1.81% | 243,035 | $5.2M | Reduce -1.2% |
| ERAS Erasca Inc. | 1.74% | 2,427,184 | $5.0M | New |
| XFOR X4 Pharmaceuticals Inc. | 1.74% | 3,588,427 | $5.0M | No change |
| NUVB Nuvation Bio Inc. | 1.69% | 1,336,231 | $4.9M | New |
| SRRK Scholar Rock Holding Corp. | 1.69% | 273,720 | $4.9M | New |
| IART Integra Lifesciences Holding | 1.69% | 137,000 | $4.9M | New |
| OCUL Ocular Therapeutix Inc. | 1.21% | 383,026 | $3.5M | Reduce -60.6% |
| CTMX Cytomx Therapeutics Inc. | 1.21% | 1,598,590 | $3.5M | New |
| ENTA Enanta Pharmaceuticals Inc. | 1.08% | 177,004 | $3.1M | New |
| STOK Stoke Therapeutics Inc. | 1.06% | 225,496 | $3.0M | New |
| MODULAR MED INC | 0.99% | 1,539,352 | $2.8M | Add +123.3% |
| RAPT THERAPEUTICS INC | 0.99% | 315,000 | $2.8M | New |
| RVNC Revance Therapeutics Inc. | 0.80% | 468,871 | $2.3M | New |
| VTYX Ventyx Biosciences Inc. | 0.72% | 378,000 | $2.1M | New |
| BOLD Boundless Bio Inc. | 0.71% | 143,000 | $2.0M | New |
| APRE Aprea Therapeutics Inc. | 0.64% | 276,603 | $1.9M | Reduce -1.2% |
| THRD Third Harmonic Bio Inc. | 0.54% | 163,363 | $1.5M | No change |
| PRLD Prelude Therapeutics Inc. | 0.53% | 320,394 | $1.5M | No change |
| IDYA Ideaya Biosciences Inc. | 0.50% | 33,007 | $1.4M | No change |
| IRWD Ironwood Pharmaceuticals Inc. | 0.45% | 149,400 | $1.3M | New |
| FHTX Foghorn Therapeutics Inc. | 0.28% | 121,672 | $816K | No change |
| NYXH Nyxoah SA | 0.24% | 50,839 | $686K | Reduce -74.6% |
| VINCERX PHARMA INC | 0.18% | 102,049 | $516K | No change |
| NXTC Nextcure Inc. | 0.10% | 130,000 | $290K | No change |
| AVTX Avalo Therapeutics Inc. | 0.08% | 10,151 | $221K | New |
| ASLAN PHARMACEUTICALS LTD | 0.05% | 254,150 | $156K | No change |
Options reported separately and not counted above: INSM puts ($37.0M), IRWD puts ($8.5M), PCRX puts ($3.3M).
Other holdings (3): bonds, preferreds, convertibles and warrants · $141K (not counted above)
Total filed on the 13F, all lines: $287.1M.
Portfolio Sells Q4 2023 → Q1 2024
| MRTX Mirati Therapeutics Inc. | Sold out | 0.00% | −21.97 |
| GRCL Gracell Biotechnologies-ADR | Sold out | 0.00% | −12.94 |
| IMGN Immunogen Inc. | Sold out | 0.00% | −4.92 |
| UTHR United Therapeutics Corp. | Sold out | 0.00% | −4.53 |
| PTGX Protagonist Therapeutics Inc. | Sold out | 0.00% | −2.72 |
| GSK GSK PLC-Spon ADR | Reduce -53.9% | 3.94% | −1.52 |
| MACK Merrimack Pharmaceuticals Inc. | Sold out | 0.00% | −1.00 |
| EMBC Embecta Corp. | Reduce -20.5% | 2.71% | −0.88 |
| HARP Harpoon Therapeutics Inc. | Sold out | 0.00% | −0.87 |
| CMPS Compass Pathways PLC | Sold out | 0.00% | −0.57 |
| HCSG Healthcare Services Group | Reduce -48.0% | 1.83% | −0.33 |
| CRBP Corbus Pharmaceuticals Holdi | Sold out | 0.00% | −0.23 |
| VNDA Vanda Pharmaceuticals Inc. | Sold out | 0.00% | −0.11 |
| INGN Inogen Inc. | Sold out | 0.00% | −0.07 |
| CAREMAX INC | Sold out | 0.00% | −0.00 |
| NYXH Nyxoah SA | Reduce -74.6% | 0.24% | −0.00 |
| GMED Globus Medical Inc. Class A | Reduce -26.1% | 7.35% | +0.05 |
| OCUL Ocular Therapeutix Inc. | Reduce -60.6% | 1.21% | +0.10 |
| APRE Aprea Therapeutics Inc. | Reduce -1.2% | 0.64% | +0.31 |
| TFX Teleflex Inc. | Reduce -7.3% | 2.67% | +0.32 |
| SPRY Ars Pharmaceuticals Inc. | Reduce -51.5% | 1.91% | +0.35 |
| CI The Cigna Group | Reduce -34.7% | 9.63% | +0.64 |
| FUSN Fusion Pharmaceuticals Inc. | Reduce -1.2% | 1.81% | +1.20 |
Portfolio Buys Q4 2023 → Q1 2024
| LH Laboratory CRP of Amer Hldgs | Add +36.8% | 17.20% | +7.53 |
| MDGL Madrigal Pharmaceuticals Inc. | New | 4.75% | +4.75 |
| MDT Medtronic PLC | New | 3.19% | +3.19 |
| OGN Organon & Co. | New | 3.14% | +3.14 |
| TYRA Tyra Biosciences Inc. | New | 3.06% | +3.06 |
| HUMA Humacyte Inc. | New | 2.17% | +2.17 |
| ANIP Ani Pharmaceuticals Inc. | New | 2.10% | +2.10 |
| ATXS Astria Therapeutics Inc. | New | 2.01% | +2.01 |
| APGE Apogee Therapeutics Inc. | New | 1.81% | +1.81 |
| ERAS Erasca Inc. | New | 1.74% | +1.74 |
| NUVB Nuvation Bio Inc. | New | 1.69% | +1.69 |
| SRRK Scholar Rock Holding Corp. | New | 1.69% | +1.69 |
| IART Integra Lifesciences Holding | New | 1.69% | +1.69 |
| CTMX Cytomx Therapeutics Inc. | New | 1.21% | +1.21 |
| ZBH Zimmer Biomet Holdings Inc. | Add +2.6% | 3.41% | +1.14 |
| ENTA Enanta Pharmaceuticals Inc. | New | 1.08% | +1.08 |
| STOK Stoke Therapeutics Inc. | New | 1.06% | +1.06 |
| RAPT THERAPEUTICS INC | New | 0.99% | +0.99 |
| BBIO Bridgebio Pharma Inc. | Add +54.2% | 2.19% | +0.82 |
| RVNC Revance Therapeutics Inc. | New | 0.80% | +0.80 |
| VTYX Ventyx Biosciences Inc. | New | 0.72% | +0.72 |
| BOLD Boundless Bio Inc. | New | 0.71% | +0.71 |
| MODULAR MED INC | Add +123.3% | 0.99% | +0.67 |
| IRWD Ironwood Pharmaceuticals Inc. | New | 0.45% | +0.45 |
| AVTX Avalo Therapeutics Inc. | New | 0.08% | +0.08 |
Options Activity Q4 2023 → Q1 2024
| INSM Insmed Inc. | put | Add +58.1% | 1,362,700 | $37.0M |
| SRPT Sarepta Therapeutics Inc. | put | Sold out | 141,300 | $13.6Mbefore exit |
| NEOG Neogen Corp. | put | Sold out | 427,000 | $8.6Mbefore exit |
| IRWD Ironwood Pharmaceuticals Inc. | put | Add +494.1% | 970,800 | $8.5M |
| PCRX Pacira Biosciences Inc. | put | New | 112,000 | $3.3M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 55 | $583.5M | AVR, COR, MMS, ALLO, GMED |
| Q1 2026 | 71 | $693.9M | MMS, WAY, ICLR, COR, DNTH |
| Q4 2025 | 63 | $603.1M | CELC, CI, SNY, MMS, ZBH |
| Q3 2025 | 49 | $395.1M | MMS, CELC, SNY, DNTH, ALKS |
| Q2 2025 | 47 | $249.1M | MMS, IRON, GMED, CNC, MRK |
| Q1 2025 | 51 | $330.2M | ICLR, MMS, MRK, ZBH, NBIX |
| Q4 2024 | 49 | $355.3M | ICLR, MMS, CI, LH, SNY |
| Q3 2024 | 35 | $223.1M | LH, TEVA, MMS, ZBH, VXRT |
| Q2 2024 | 43 | $265.1M | LH, TFX, ZBH, SNN, OGN |
| Q1 2024 | 45 | $287.0M | LH, CI, GMED, MDGL, GSK |